Scotland Okays First ILAP Drugs For Reimbursement
Executive Summary
The Scottish Medicines Consortium has recommended Gilead’s Trodelvy, Amgen’s Lumykras and Pfizer’s Lorviqua for use on the Scottish National Health Service.
You may also be interested in...
Project Orbis: More Cancer Drugs Available In Scotland Than England
The UK joined Project Orbis in 2021 with the aim of speeding up the regulatory process for promising cancer drugs, but fewer than half of the drugs licensed under this pathway are available on the NHS in England.
Scotland First To OK Reimbursement For MSD's Welireg, But Situation In England Remains Unclear
The SMC, the Scottish health technology assessment body, has approved reimbursement for the first drug to win an innovation passport from the UK regulator.
The Evolution Of Drug Regulation In Post-Brexit Britain
Regulatory reliance is playing an increasingly important role in gaining marketing authorization in the UK following Brexit. Meanwhile, the country’s unique Innovative Licensing and Access Pathway is attracting growing levels of interest, not just from companies but from regulators and health technology appraisal bodies across the world.